Key Performance Indicators
PRIMARY
Hazard Ratio (Death)
0.76
95% CI: 0.63–0.93
Significant Survival Benefit
PRIMARY
Median OS (Ribociclib)
63.9
Months
>1 Year improvement vs Placebo
P-Value
0.008
Two-sided
Statistically Significant
6-Year Survival Rate
44.2%
Ribociclib Arm
vs 32.0% Placebo
01
Median Overall Survival: Ribociclib Extends Life by Over 12 Months
Patients receiving Ribociclib lived a median of 63.9 months compared to 51.4 months for placebo, a clinically meaningful extension of life in the first-line setting.
02
Survival Benefit Widens Over Time (Landmark Analysis)
The absolute difference in survival rates increases from 5.7% at 4 years to 12.2% at 6 years, demonstrating sustained long-term benefit.
03
Consistent Survival Benefit Across Key Subgroups
The hazard ratio favors Ribociclib across stratification factors, including age and site of metastasis. Note: Wide CIs in smaller subgroups.
04
Ribociclib Delays Need for Chemotherapy by ~1 Year
Treatment significantly extended both the time to first subsequent chemotherapy and chemotherapy-free survival compared to placebo.
05
Safety Profile: Higher Neutropenia but Manageable
Grade 3/4 adverse events of special interest were more frequent with Ribociclib, primarily driven by neutropenia, while other severe events remained low.
06
Impact of Subsequent CDK4/6 Inhibitor Use
Despite 34.4% of placebo patients receiving a CDK4/6 inhibitor after progression (vs 21.7% in the Ribociclib arm), the OS benefit remained significant.
Editorial Conclusion
“Ribociclib plus letrozole demonstrates a statistically significant and clinically meaningful overall survival benefit of over 12 months compared to placebo.”
Median OS of 63.9 months is the longest reported in this setting.
Benefit is consistent across subgroups and maintained despite high crossover to CDK4/6 inhibitors in the control arm.
Delays time to chemotherapy by approximately one year.
Clinical Implication
These results support the use of Ribociclib plus Letrozole as a standard-of-care first-line therapy for postmenopausal patients with HR+, HER2- advanced breast cancer.
Reference Data & Sources
Complete Data Table
| viz_id | chart_type | label | group | value | value_text | low | high | sd | p | sig | unit | category | x | y | target | rank |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| viz1 | dumbbell | Median Overall Survival | Ribociclib + Letrozole | 63.9 | 63.9 mo | 52.4 | 71.0 | months | ||||||||
| viz1 | dumbbell | Median Overall Survival | Placebo + Letrozole | 51.4 | 51.4 mo | 47.2 | 59.7 | months | ||||||||
| viz2 | line_chart | 48 Months | Ribociclib + Letrozole | 60.9% | % | 48 | 60.9 | |||||||||
| viz2 | line_chart | 60 Months | Ribociclib + Letrozole | 52.3% | % | 60 | 52.3 | |||||||||
| viz2 | line_chart | 72 Months | Ribociclib + Letrozole | 44.2% | % | 72 | 44.2 | |||||||||
| viz2 | line_chart | 48 Months | Placebo + Letrozole | 55.2% | % | 48 | 55.2 | |||||||||
| viz2 | line_chart | 60 Months | Placebo + Letrozole | 43.9% | % | 60 | 43.9 | |||||||||
| viz2 | line_chart | 72 Months | Placebo + Letrozole | 32.0% | % | 72 | 32.0 | |||||||||
| viz3 | forest | All Patients | Overall | 0.76 | 0.63 | 0.93 | Summary | |||||||||
| viz3 | forest | Age <65 Yr | Age | 0.73 | 0.56 | 0.94 | Demographic | |||||||||
| viz3 | forest | Age ≥65 Yr | Age | 0.81 | 0.6 | 1.12 | Demographic | |||||||||
| viz3 | forest | Visceral Metastasis (Liver/Lung) | Disease Site | 0.81 | 0.62 | 1.05 | Clinical | |||||||||
| viz3 | forest | Bone Lesion Only | Disease Site | 0.78 | 0.5 | 1.21 | Clinical | |||||||||
| viz3 | forest | Prior Chemo (No) | History | 0.74 | 0.56 | 0.98 | Clinical | |||||||||
| viz4 | grouped_bar | Time to 1st Chemo | Ribociclib + Letrozole | 50.6 | months | |||||||||||
| viz4 | grouped_bar | Time to 1st Chemo | Placebo + Letrozole | 38.9 | months | |||||||||||
| viz4 | grouped_bar | Chemo-Free Survival | Ribociclib + Letrozole | 39.9 | months | |||||||||||
| viz4 | grouped_bar | Chemo-Free Survival | Placebo + Letrozole | 30.1 | months | |||||||||||
| viz5 | diverging_bar | Neutropenia (G3/4) | Ribociclib + Letrozole | 63.8 | % | |||||||||||
| viz5 | diverging_bar | Neutropenia (G3/4) | Placebo + Letrozole | -1.2 | 1.2% | % | ||||||||||
| viz5 | diverging_bar | Hepatobiliary Toxicity (G3/4) | Ribociclib + Letrozole | 14.4 | % | |||||||||||
| viz5 | diverging_bar | Hepatobiliary Toxicity (G3/4) | Placebo + Letrozole | -4.8 | 4.8% | % | ||||||||||
| viz5 | diverging_bar | Prolonged QT Interval (G3/4) | Ribociclib + Letrozole | 4.5 | % | |||||||||||
| viz5 | diverging_bar | Prolonged QT Interval (G3/4) | Placebo + Letrozole | -2.1 | 2.1% | % | ||||||||||
| viz6 | proportional_bar | Subsequent CDK4/6 Use | Ribociclib + Letrozole | 21.7 | % | Received CDK4/6 | ||||||||||
| viz6 | proportional_bar | No Subsequent CDK4/6 | Ribociclib + Letrozole | 78.3 | % | Did Not Receive | ||||||||||
| viz6 | proportional_bar | Subsequent CDK4/6 Use | Placebo + Letrozole | 34.4 | % | Received CDK4/6 | ||||||||||
| viz6 | proportional_bar | No Subsequent CDK4/6 | Placebo + Letrozole | 65.6 | % | Did Not Receive |
Abbreviations
| Abbrev | Meaning |
|---|---|
| OS | Overall Survival |
| HR | Hazard Ratio |
| CI | Confidence Interval |
| CDK4/6 | Cyclin-dependent kinases 4 and 6 |
| AE | Adverse Event |
Source
N Engl J Med 2022;386:942-50
DOI: 10.1056/NEJMoa2114663
Limitations
- Underrepresentation of Black patients (2.5%)
- Wide confidence intervals in smaller subgroups
- Exploratory nature of time-to-chemotherapy endpoints